Effects of mosapride on esophageal functions and gastroesophageal reflux
| Autor: | Kyoichi Adachi, Shunji Ohara, Yoshikazu Kinoshita, Shuji Nakata, Takashi Tanimura, Kenji Furuta, Kenji Koshino, Terumi Morita, Masaharu Miki |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Hepatology medicine.diagnostic_test business.industry Esophageal disease Anti-ulcer Agent medicine.medical_treatment Gastroenterology Reflux Prokinetic agent medicine.disease Crossover study Mosapride medicine.anatomical_structure Internal medicine Medicine Esophagus business Esophageal pH monitoring medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 25:1066-1071 |
| ISSN: | 0815-9319 |
| DOI: | 10.1111/j.1440-1746.2010.06280.x |
| Popis: | Background and Aim: A substantial number of patients with gastroesophageal reflux disease show symptomatic resistance to high-dose proton pump inhibitors. In those cases, prokinetics are possible candidates for treatment. The aim of the present study was to determine whether mosapride, a prokinetic agent, stimulates esophageal functions, and prevents acidic and non-acidic gastroesophageal reflux. Methods: Normal volunteers (nine and 13 for two experiments, respectively) were enrolled. Salivary secretion, esophageal peristaltic contractions, and resting lower esophageal sphincter pressure with and without mosapride administration were recorded using a cross-over protocol. Post-prandial acidic and non-acidic reflux levels were also recorded. Results: Mosapride at a standard dose of 15 mg/day did not stimulate salivary secretion or any esophageal motor functions. It also failed to prevent acidic and non-acidic post-prandial gastroesophageal reflux. Conclusions: Mosapride at 15 mg/day, a standard dose in Japan, did not change the esophageal motility and salivary secretion in healthy volunteers. Future study on a larger number of individuals with higher dose of mosapride is worthwhile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text